Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 28;13(8):1652.
doi: 10.3390/life13081652.

Subcutaneous Implantable Cardioverter Defibrillator: A Contemporary Overview

Affiliations
Review

Subcutaneous Implantable Cardioverter Defibrillator: A Contemporary Overview

Fabrizio Guarracini et al. Life (Basel). .

Abstract

The difference between subcutaneous implantable cardioverter defibrillators (S-ICDs) and transvenous ICDs (TV-ICDs) concerns a whole extra thoracic implantation, including a defibrillator coil and pulse generator, without endovascular components. The improved safety profile has allowed the S-ICD to be rapidly taken up, especially among younger patients. Reports of its role in different cardiac diseases at high risk of SCD such as hypertrophic and arrhythmic cardiomyopathies, as well as channelopathies, is increasing. S-ICDs show comparable efficacy, reliability, and safety outcomes compared to TV-ICD. However, some technical issues (i.e., the inability to perform anti-bradycardia pacing) strongly limit the employment of S-ICDs. Therefore, it still remains only an alternative to the traditional ICD thus far. This review aims to provide a contemporary overview of the role of S-ICDs compared to TV-ICDs in clinical practice, including technical aspects regarding device manufacture and implantation techniques. Newer outlooks and future perspectives of S-ICDs are also brought up to date.

Keywords: cardiomyopathy; subcutaneous implantable cardioverter defibrillator; sudden death; ventricular tachycardia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Advantages of S-ICD over TV-ICD.

References

    1. Alter P., Waldhans S., Plachta E., Moosdorf R., Grimm W. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin. Electrophysiol. 2005;28:926–932. doi: 10.1111/j.1540-8159.2005.00195.x. - DOI - PubMed
    1. Bardy G.H., Smith W.M., Hood M.A., Crozier I.G., Melton I.C., Jordaens L., Theuns D., Park R.E., Wright D.J., Connelly D.T., et al. An Entirely Subcutaneous Implantable Cardioverter–Defibrillator. N. Engl. J. Med. 2010;363:36–44. doi: 10.1056/NEJMoa0909545. - DOI - PubMed
    1. Dabiri Abkenari L., Theuns D.A., Valk S.D., Van Belle Y., de Groot N.M., Haitsma D., Muskens-Heemskerk A., Szili-Torok T., Jordaens L. Clinical experience with a novel subcutaneous implantable defibrillator system in a single center. Clin. Res. Cardiol. 2011;100:737–744. doi: 10.1007/s00392-011-0303-6. - DOI - PMC - PubMed
    1. De Filippo P., Migliore F., Palmisano P., Nigro G., Ziacchi M., Rordorf R., Pieragnoli P., Di Grazia A., Ottaviano L., Francia P., et al. Procedure, management, and outcome of subcutaneous implantable cardioverter–defibrillator extraction in clinical practice. EP Eur. 2023;25:euad158. doi: 10.1093/europace/euad158. - DOI - PMC - PubMed
    1. Kuschyk J., Müller-Leisse J., Duncker D., Tülümen E., Fastenrath F., Fastner C., Kruska M., Akin I., Liebe V., Borggrefe M., et al. Comparison of transvenous vs subcutaneous defibrillator therapy in patients with cardiac arrhythmia syndromes and genetic cardiomyopathies. Int. J. Cardiol. 2021;323:100–105. doi: 10.1016/j.ijcard.2020.08.089. - DOI - PubMed

LinkOut - more resources